Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.

Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.

Publication date: May 10, 2019

Maeda, T., Yoshino, K., Nagai, K., Oaku, S., Kato, M., Hiura, A., and Hata, H. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy. 22634. 2019 Eur J Cancer (115):

Concepts Keywords
Endocrine Combination therapy
Melanoma Melanoma
Monotherapy Nivolumab
Antineoplastic drugs
Breakthrough therapy
Bristol-Myers Squibb
Health
Clinical medicine
Medicine
Survival advanced melanoma

Semantics

Type Source Name
drug DRUGBANK Nivolumab
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease MESH Development

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *